Salute e Benessere

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515…

"SKY-0515 provides exciting potential for Huntington's disease patients and leads a growing pipeline of RNA-targeting therapies developed by our SKYSTAR® platform," said Bill Haney, CEO and Co-Founder of Skyhawk Therapeutics. "Huntington's patients presently have few therapeutic options and none that reverse or slow disease progression. SKY-0515 has demonstrated strong activity in our preclinical models which we believe will translate to patient benefit." "SKY-0515…
PR Newswire
23/10/2023

Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase…

SAN DIEGO and CALGARY, AB, Oct. 23, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY),( Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the poster presentation of positive, updated results from the Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma (PDAC) at the European Society for Medical Oncology meeting (ESMO 2023), taking place in Madrid, Spain. SAN...
PR Newswire
23/10/2023

Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal…

"The results presented at ESMO met the criteria to advance the study to the next stage, with 4 of 14 enrolled patients demonstrating stable disease at week 16. These data demonstrated a 40% overall disease control rate and provided further encouraging data for pelareorep," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. "In a patient population that had failed multiple rounds of treatment, we continue to see pelareorep's ability to synergize with…
PR Newswire
23/10/2023

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating…

-Results show enhanced patient survival, correlating with VCN-01 mediated increases in the CPS score, a key determinant of outcomes with anti-PD-(L)1 checkpoint inhibitor therapies- -Key Opinion Leader (KOL) webinar featuring expert oncologist RicardMesia M.D., Ph.D., to be held today, Monday, October 23, 2023 at 8:00 a.m. ET- ROCKVILLE, Md., Oct.23, 2023(GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company...
Nasdaq GlobeNewswire
23/10/2023

Integration of Technology into Baby Bottles to Drive Demand in the Baby Bottle…

The baby bottle market is predicted to be valued at US$ 3.41 billion in 2023 and US$ 5 billion by 2033. Over the projection period, sales in the baby bottle market are expected to increase at a CAGR of 3.9%. The baby bottle market is predicted to be valued atUS$ 3.41 billionin 2023 andUS$ 5 billionby 2033. Over the projection period, sales in the baby bottle market are expected to increase at a CAGR of 3.9%. Get the Sample PDF Summary to obtain an overview of the Comprehensive...
PR Newswire
23/10/2023

BioNTech to Report Third Quarter Financial Results and Corporate Update on…

MAINZ, Germany , October 23, 2023(GLOBE NEWSWIRE)– BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2023 on Monday, November 6 th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter 2023. To access the live conference...
Nasdaq GlobeNewswire
23/10/2023

Luoxin Pharmaceutical's LX-039 (Innovative Anti-Tumor Drug): Phase I Clinical…

LX-039 is an innovative selective estrogen receptor degrader (SERD) for oral administration. The aims of the dose escalation and expansion phase I study was to explore the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) profiles of LX-039 in postmenopausal patients with ER+ and HER2- advanced breast cancer who have failed endocrine therapy. The study was led by Professor Hu Xichun from Fudan University Shanghai Cancer Center. LX-039 is an innovative…
PR Newswire
23/10/2023

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and…

The two assays are the collaborative effort of Mindray and HyTest, a Mindray company and a prominent global provider of antibodies and antigens. HyTest, renowned for its cardiac biomarker expertise, had its cardiac troponin complex material selected as the international troponin standard by AACC in 2004. The two assays are the collaborative effort of Mindray and HyTest, a Mindray company and a prominent global provider of antibodies and antigens. HyTest, renowned for its cardiac biomarker...
PR Newswire
23/10/2023

MAR Weekly Report_VIRBAC SA_16 to 20 October 2023

Statement of transactions in own shares from 2023-10-16 to 2023-10-20BNP PARIBAS Aggregated presentation by day and by market Name of issuerIdentification code of issuer (Legal Entity Identifier)Day of transactionIdentification code of financial instrumentAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares...
Nasdaq GlobeNewswire
23/10/2023

Asthma Biologics Market Predicted to Reach USD 19.2 billion by 2031, Growing at…

Asthma biologics are shifting towards personalized treatment regimens. With advances in biomarker identification, physicians can better match patients with the right biologic therapy. This tailoring of treatment can lead to improved efficacy and reduced side effects, opening doors for further research and development in this area. Asthma biologics are shifting towards personalized treatment regimens. With advances in biomarker identification, physicians can better match patients with the…
PR Newswire
23/10/2023

CDR-Life Presents Precise Tumor and Patient Selection for CDR404…

- CDR404 represents a potential paradigm shift in the development of T-cell engagers for solid cancers - Epithelial cancer indications eligible for CDR404 Phase 1 trial include non-small cell lung carcinoma (NSCLC), head & neck squamous cell carcinoma and bladder cancer ZÜRICH, Switzerland, Oct.23, 2023(GLOBE NEWSWIRE) --CDR-Life Inc.presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a...
Nasdaq GlobeNewswire
23/10/2023

Celebrate China's Double Ninth Festival with the 134th Canton Fair and Explore…

Presented at the 134th Canton Fair by Kaiping Rainparty Sanitary Ware Technology Co., LTD. ("Rainparty"), the Chrome Plated Thermostatic Shower Set is a remarkable product, featuring an 8-inch slender round overhead shower head and a handheld sprayer that are both easy to clean and highly effective in preventing clogs. The handle of the shower set is equipped with a thermostatic faucet, handheld sprayer switch, and water temperature adjustment button, ensuring effortless operation…
PR Newswire
23/10/2023

Michigan Medicine harnesses the power of Sectra's digital pathology solution to…

The pathology solution is part of Sectra's enterprise imaging solution, which provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Visit Sectra's website to read more about Sectra and why it's top-ranked in "Best in KLAS". The pathology solution is part of Sectra's enterprise imaging solution, which provides…
PR Newswire
23/10/2023

Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001…

"The favorable safety and tolerability profile of HMBD-001 and its monotherapy activity in biomarker-unselected cohorts are very encouraging and shows that HMBD-001 is an active antibody that effectively inhibits HER3 signaling, which has been shown to be important for cancer growth and survival. HMBD-001 is designed to be a best-in-class HER3 antibody with a differentiated mechanism of action, leveraging knowledge around HER3 biology built up by Hummingbird Bio over the years. To optimize…
PR Newswire
23/10/2023

Jonathan Milner Issues Statement Responding to the Glass Lewis Report

Jonathan Milner Issues Statement Responding to the Glass Lewis ReportWelcomes the Glass Lewis report's observations on the disproportionate rewards for Abcam's Executive Directors and on the identified issues with peer group valuation strategiesUrges Shareholders to continue toVote AGAINSTthe current proposed acquisition of Abcam by DanaherCAMBRIDGE, England, 23 October 2023– Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the...
Nasdaq GlobeNewswire
23/10/2023

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer…

Strategic Collaborator-presented Phase 1 Pancreatic Cancer DataAn ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer (LAPC) established a favorable safety profile and recommended dose23 months median Overall Survival (mOS) observed in 17 patients treated with cytotoxic chemotherapy followed by RT-activated NBTXR3 Review of an historical control from the same center as this Phase 1 in 243 patients with LAPC showed an mOS of 19.2 months in 144...
Nasdaq GlobeNewswire
23/10/2023

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at…

In addition, on October 21st, Dr. Oddbjorn Straume, M.D., Ph.D., Assistant Professor, Clinical Science at the Haukeland University Hospital in Bergen, Norway presented results of the Investigator Led Study LBA52 of bemcentinib in addition to pembrolizumab or the targeted therapies dabrafenib/trametinib in 1L and 2L metastatic melanoma patients. In addition, onOctober 21st, Dr. Oddbjorn Straume, M.D., Ph.D., Assistant Professor, Clinical Science at the Haukeland University Hospital in...
PR Newswire
23/10/2023

Nanoform grant Global STARMAP® AI License to AstraZeneca

As part of this licensing agreement, Nanoform will receive access to compound libraries and large data sets to undertake STARMAP® screening and propose innovative product development concepts and strategies in collaboration with AstraZeneca. As part of this licensing agreement, Nanoform will receive access to compound libraries and large data sets to undertake STARMAP ®screening and propose innovative product development concepts and strategies in collaboration with AstraZeneca. This comes...
PR Newswire
23/10/2023

[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive…

Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitisRoche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody,...
Nasdaq GlobeNewswire
23/10/2023

Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in…

Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay® (odevixibat) based on Phase III ASSERT clinical-trial data in Alagille syndrome (ALGS) already received in July 2023Committee for Orphan Medicinal Products confirms a negative opinion of its review recommending not to maintain the orphan designation for Bylvay in ALGSIpsen plans to submit a new Marketing Authorisation Application for the treatment of ALGS by the end of 2023 under a...
Nasdaq GlobeNewswire
23/10/2023

Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under…

Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE ®licensing agreementRelates to the submission of a marketing approval application in JapanMarks strong progress in 2016 agreement and further boosts Mithra's cash positionAdditional EUR 10 million in milestone payments expected at approval of marketing authorizationMithra eligible for revenue from supply of the manufactured product post-commercializationLiege, Belgium, 23...
Nasdaq GlobeNewswire
23/10/2023

Philips delivers strong sales growth, profitability and cash flow; raises…

Third-quarter highlightsGroup sales increased 11% on a comparable basis to EUR 4.5 billionIncome from operations at EUR 224 million, compared to a loss of EUR 1,529 million in Q3 2022Adjusted EBITA increased to EUR 457 million, or 10.2% of sales, compared to EUR 209 million, or 4.8% of sales, in Q3 2022Comparable order intake was -9% compared to Q3 2022; order book remains strongOperating cash flow improved to EUR 489 million, compared to an outflow of EUR 180 million in Q3...
Nasdaq GlobeNewswire
23/10/2023

Ultimovacs Provides Complete Phase II NIPU Results Presented at ESMO 2023…

UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, met the study protocol's predefined threshold for statistical significance and demonstrated a clinically meaningful overall survival benefit with no added toxicities, compared to ipilimumab and nivolumab alone, in the second-line treatment of patients with malignant mesotheliomaFirst demonstration of universal cancer vaccine efficacy in randomized Phase II clinical trial; Proof of...
Nasdaq GlobeNewswire
23/10/2023

Idorsia is committed to further the science of sleep with a symposium and poster…

Allschwil, Switzerland – October 23, 2023Idorsia Ltd (SIX: IDIA) today announced that it is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023, a global scientific congress bringing the best of sleep medicine and research to Rio de Janeiro, Brazil, October 20-25.An Industry Symposium entitled "Managing chronic insomnia disorder – what have we learned from clinical trials and real-world practice?" will be hosted by Idorsia on…
Nasdaq GlobeNewswire
23/10/2023
Altri  Comunicati